UAE Ministry of Investment participates in third GCC Investment Committee Meeting
UAE reaffirmed its commitment to strengthening regional investment coordination
Abu Dhabi – The UAE Ministry of Investment, represented by His Excellency Mohammad Abdulrahman Alhawi, Undersecretary at the Ministry of Investment, participated in the third Gulf Cooperation Council (GCC) Investment Committee Meeting, held on 13 April 2025 in Kuwait.
The meeting brought together GCC Ministry of Investment Undersecretaries to discuss aligning investment strategies and enhancing the region's appeal to global investors in light of the region's growing portfolio of investment opportunities. The discussions built on shared ambitions to improve coordination and harmonise legislative and regulatory frameworks, with the aim of strengthening the GCC's position as a globally competitive investment destination.
His Excellency Mohammad Abdulrahman Alhawi, Undersecretary at the UAE Ministry of Investment, stated: 'The UAE is committed to continue working closely with its GCC partners to unlock new pathways for joint investment promotion, drive sustainable growth, and enhance the region's global competitiveness. As the GCC continues to expand its collective capacity to attract international investments, deepening economic integration is key to building a resilient and future-ready investment ecosystem across the region.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
11 hours ago
- Zawya
Kuwait crude oil gain 95 cents Mon. to $64.56 pb
RELATED TOPICS OIL COMMODITIES KUWAIT GCC GCC COUNTRIES OIL KUWAIT-- Kuwait crude oil gained 95 cents during Monday's trading to reach USD 64.56 per barrel compared with 63.61 pb last Friday, Kuwait Petroleum Corporation (KPC) said Tuesday. Brent futures rose USD 1.85 to USD 64.63 pb and West Texas Intermediate increased by 1.73 to USD 62.52 pb. All KUNA right are reserved © 2022. Provided by SyndiGate Media Inc. (
Zawya
12 hours ago
- Zawya
EIGHTClouds announces strategic milestone with $20mln raised and plans for sector-focused expansion
Dubai, UAE – EIGHTClouds is pleased to announce the successful completion of its targeted US$20 million capital raise, originally structured as a 24-month initiative, completed in just 11 months due to strong strategic interest and oversubscription. This milestone reinforces our positioning as a disciplined, sector-focused investment platform and reflects growing confidence in our consumer-centric approach across the region. Capital from the raise is being deployed across a series of strategic acquisitions, with several investments already completed and others in progress. These efforts align with our long-term vision to support category-defining companies across the Gulf Cooperation Council (GCC) and beyond. Over the past year, EIGHTClouds has intensified its activity in high-growth verticals within Food & Beverage and Hospitality, sectors where evolving consumer preferences, digital innovation, and operational scale are creating meaningful opportunities. To build on this momentum, we are preparing a new series of sector-focused investment initiatives, with Cayman-based structures under consideration, to deepen our exposure to the consumer sector. These initiatives will initially concentrate on scalable F&B concepts, hospitality models, and experience-led brands aligned with evolving regional and global consumer trends, including a strategy focused on No Exit Plan (NEP) businesses. These established, family-owned businesses with no clear succession plan are often under-managed but rich in brand equity and customer loyalty, and represent untapped potential across retail, food & beverage, wellness, and direct-to-consumer sectors. 'This past year has marked a phase of disciplined expansion for EIGHTClouds,' said Mark Aitchison, Founder & CEO. 'We have supported businesses with strong fundamentals, clear market differentiation, and the potential to grow into regional leaders. These upcoming initiatives reflect our conviction in long-term opportunities within the consumer space, and our commitment to building resilient, high-quality brands across the region.' The upcoming structures aim to increase EIGHTClouds' involvement in fast-growing, consumer-facing businesses with strong cash flow potential, scalable commercial models, and clear strategic pathways. With favourable demographics, rising discretionary income, and a pro-business policy environment, the GCC continues to provide an attractive backdrop for targeted growth efforts. 'Across our pipeline, we are seeing strong consumer businesses with both regional relevance and global scalability,' said Oliver Wall, Director of Investments at EIGHTClouds. 'What sets them apart is a clear business model, solid market positioning, and the ability to scale efficiently. Through our upcoming initiatives, we intend to support this potential with capital, executional support, and strategic alignment.' EIGHTClouds' approach remains centred on high-conviction ownership, operational involvement, and long-term value creation. By supporting exceptional companies with tools to scale, including technology, branding, distribution, and capital discipline, the firm is carving out a distinct position within the GCC's alternative investment landscape. These initiatives will also serve as a launchpad for regional expansion, with a focus on the UAE, Saudi Arabia, and key gateway markets where consumer demand, infrastructure, and policy reform are converging to shape the next wave of opportunity in the consumer economy. EIGHTClouds Disclaimer: This communication is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or investment products. Any forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties.
Arabian Business
14 hours ago
- Arabian Business
Inside Insilico's bid to create the UAE's first homegrown cancer drug
Clinical-stage biotech company Insilico Medicine recently announced it will attempt to discover the first novel cancer drug developed entirely in the United Arab Emirates with just four scientists and its proprietary AI platform to complete work that traditionally takes hundreds of researchers and years of effort. The Abu Dhabi-based team aims to identify promising cancer targets, design new molecules, and prepare a complete preclinical data package within 18 months—a process that typically takes pharmaceutical companies three to five years and costs hundreds of millions of dollars. 'Our Masdar City centre already hosts around 60 AI and biotech specialists. By tasking four of them with a complete end-to-end discovery run, we aim to prove that any GCC nation equipped with cloud compute, wet-lab automation and local talent can create world-class therapeutics,' Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, told Arabian Business. The initiative represents both a scientific experiment and a geopolitical statement as it has the potential to transform the Middle East's role in global pharmaceutical development while challenging fundamental assumptions about where and how drug discovery can occur in the AI era. Four scientists, one AI The team consists of two computational chemists, one medicinal chemist, and one translational biologist – a deliberately lean operation working alongside Insilico's proprietary AI system, They are targeting what the company describes as 'medium-novelty and genetically validated synthetic-lethality targets' for solid tumours –essentially, seeking ways to kill cancer cells by exploiting specific genetic vulnerabilities. In pharmaceutical terms, the team is working at breakneck speed. Their roadmap calls for finalising a biological target by Q3 2025, generating promising molecular structures in under 30 days, and completing the entire preclinical package within 18 months. Traditional drug discovery typically takes three to five years just to reach the preclinical stage. 'Humans still design strategy and verify results, but AI handles the brute-force search, learns from every experiment in real time, and steers us away from dead ends,' explained Zhavoronkov. His description evokes a chess grandmaster working with a silicon partner—humans providing intuition and judgment, the machine crunching through billions of possibilities. Why the UAE? The choice of Abu Dhabi might seem puzzling at first. The UAE has invested heavily in healthcare infrastructure, but it remains far from established biotech hubs like Boston, San Francisco, or Cambridge. For Zhavoronkov, that's precisely the point. 'The reason we chose the UAE is because we already have a base there,' he said, referring to the AI Research and Development Centre that Insilico opened in Masdar City in 2023 with support from the Abu Dhabi Investment Office. 'UAE scientists helped discover a drug but they never tried to take full control over the drug discovery program.' This initiative – which Zhavoronkov is careful to note is self-funded by Insilico, not UAE government money – is as much about proving a concept as it is about discovering a specific drug. If a small team in Abu Dhabi can successfully identify a viable cancer treatment, it suggests that any country with sufficient computing resources and a small cadre of specialists could potentially develop life-saving medications. 'Not just lucky' Insilico's approach builds on research dating back to 2016, when the company published one of the first papers describing how generative adversarial networks (GANs) – the same AI architecture later used in image generators like DALL-E – could design novel molecules. The biotech landscape is littered with AI companies that promised to revolutionise drug discovery but delivered little. Zhavoronkov seems acutely aware of this skepticism. 'Since 2021 we have nominated 22 development candidates, advanced 10 into the clinic, completed four Phase I trials and a Phase IIa – without a single clinical failure,' he said. 'Those numbers convert skepticism into evidence.' Asked why Insilico has succeeded where others have not, Zhavoronkov pointed to four specific factors: 'Pristine, well-curated data – quantity without quality is noise; a closed experimental loop where every prediction is rapidly tested in-house and fed back to the models; deep integration of AI engineers, biologists and chemists under one roof… and many experimentally-validated AI models that we know worked in real world.' In an industry where approximately 90 per cent of drug candidates fail during development, Insilico's lead drug, Rentosertib, recently showed positive results in a Phase IIa trial for idiopathic pulmonary fibrosis (a serious lung disease that causes scarring of the lungs). The company reported that Rentosertib demonstrated favourable safety and tolerability across all dose levels, with promising early efficacy signals after just 12 weeks of treatment. In January 2025, Nature Biotechnology published a paper detailing Rentosertib's journey from AI algorithms to clinical trials – the first comprehensive account of an AI-discovered and AI-designed drug from initial concept to human testing. The company is already planning to expand across the Gulf region. Insilico recently signed a Memorandum of Understanding with Saudi Arabia's Ministry of Investment and plans to establish an operation in Riyadh by 2026, with partial funding from Aramco's Prosperity7 Ventures. The company is also in discussions with Qatar, Kuwait, Bahrain, and Oman about potential expansion. 'If the pilot hits its timelines, we will deploy identical micro-teams across the region, accelerating the sovereign drug-discovery capabilities where it matters most,' Zhavoronkov said. The bigger picture Beyond regional implications, Insilico's experiment touches on a profound question: does drug discovery still need massive teams, extensive physical infrastructure, and geographical proximity to traditional biotech clusters? 'The goal is to have multiple AI-originated drugs approved and on pharmacy shelves, with a steady stream of new candidates entering the clinic every year,' he said. '[For Insilico Medicine,] success looks like regulators, payers and physicians treating AI-designed medicines as the norm – much like jetliners are now designed in silico.' Alex Aliper, Co-Founder and President of Insilico Medicine, framed the effort in economic terms, suggesting that channelling the Gulf's 'deep technology' investments into 'life-saving medicines offers the fastest way to diversify economies and extend healthy longevity' in the region.
